Analyst Ratings for SpringWorks Therapeutics
Portfolio Pulse from Benzinga Insights
SpringWorks Therapeutics (NASDAQ:SWTX) has received positive analyst ratings in the last quarter, with 3 bullish and 1 somewhat bullish ratings. The company's average price target has increased by 53.06% from the previous average of $49.00 to $75.00.
July 20, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SpringWorks Therapeutics has received positive analyst ratings and an increased price target, indicating a positive outlook for the company.
Analyst ratings are a key indicator of a company's performance and outlook. The positive ratings and increased price target for SpringWorks Therapeutics suggest that analysts have a positive view of the company's future performance, which could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100